ArticleCell reports2021
EGF-mediated suppression of cell extrusion during mucosal damage attenuates opportunistic fungal invasion.
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Article
- A review of epidermal growth factor receptor ligands in glucose homeostasis.Frontiers in endocrinology · 2026Review
- Epigen-mediated mechanisms to alleviate glucose homeostasis disruptions in diet-induced obese and STZ-induced diabetic mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- The G-protein coupled receptor OXER1 is a tissue redox sensor essential for intestinal epithelial barrier integrity.bioRxiv : the preprint server for biology · 2025Article
- The Impact of Dimitrios P. Kontoyiannis on Mucormycosis Research.Journal of fungi (Basel, Switzerland) · 2024Article
- From Spores to Solutions: A Comprehensive Narrative Review on Mucormycosis.Diagnostics (Basel, Switzerland) · 2024Review
- Experimental Models to Study the Pathogenesis and Treatment of Mucormycosis.Journal of fungi (Basel, Switzerland) · 2024Review
- Article
- Mucormycosis in 2023: an update on pathogenesis and management.Frontiers in cellular and infection microbiology · 2023Review
- A protocol to evaluate epithelial regeneration after inducing cell loss in zebrafish larvae.STAR protocols · 2022Article
- Recent Advances and Future Directions in the Understanding of Mucormycosis.Frontiers in cellular and infection microbiology · 2022Review
- Protocol for fungal infection following the induction of epithelial cell loss in larval zebrafish.STAR protocols · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Severe and often fatal opportunistic fungal infections arise frequently following mucosal damage caused by trauma or cytotoxic chemotherapy. Interaction of fungal pathogens with epithelial cells that comprise mucosae is a key early event associated with invasion, and, therefore, enhancing epithelial defense mechanisms may mitigate infection. Here, we establish a model of mold and yeast infection mediated by inducible epithelial cell loss in larval zebrafish. Epithelial cell loss by extrusion promotes exposure of laminin associated with increased fungal attachment, invasion, and larval lethality, whereas fungi defective in adherence or filamentation have reduced virulence. Transcriptional profiling identifies significant upregulation of the epidermal growth factor receptor ligand epigen (EPGN) upon mucosal damage. Treatment with recombinant human EPGN suppresses epithelial cell extrusion, leading to reduced fungal invasion and significantly enhanced survival. These data support the concept of augmenting epithelial restorative capacity to attenuate pathogenic invasion of fungi associated with human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.